Targeting Enzymes in Psoriatic Arthritis

Psoriatic arthritis significantly impairs joint health and overall patient well-being. The intricacy of this disease is underscored by its diverse molecular mechanisms, which add layers of complexity to understanding and managing psoriatic arthritis. Utilizing Causaly, we assessed the potential of enzymes targets for psoriatic arthritis.

Psoriatic arthritis, affecting up to 1% of the global population,¹ is a chronic autoimmune disease characterized by skin and joint inflammation. The etiology of psoriatic arthritis is multifaceted, involving genetic predispositions, aberrant immune responses, and environmental triggers, which collectively contribute to disease onset and progression.

Within this complex landscape, enzymes emerge as compelling targets due to their key role in modulating biochemical reactions. Here, we used Causaly to identify and prioritize enzymes involved in the progression of psoriatic arthritis.

With 14,000+ papers on psoriatic arthritis on PubMed, identifying targets is not only challenging, but also subject to user bias. Causaly manages this data overload by machine-reading thousands of literature papers, extracting evidence for over 850 targets for psoriatic arthritis.

Using Causaly’s advanced filtering capabilities, the results were further refined by target class, revealing ~180 enzymes associated with psoriatic arthritis. The majority of these were hydrolases or transferases (Figure 1).

Psoriatic arthritis presents a significant challenge to patient health, with its complex underlying mechanisms adding layers of complexity. Our exploration underscores the potential of enzymes as therapeutic targets for this autoimmune condition.